Every material Form 8-K Guardian Pharmacy Services, Inc. has filed with the SEC since August 06, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Guardian Pharmacy Services reported third-quarter 2026 results, with revenue of $371.1 million, down 2% year-over-year and including pricing decreases from the IRA, while net income rose to $19.1 million from $9.6 million. The company raised its full-year 2026 revenue and Adjusted EBITDA guidance, which matters to shareholders because it signals higher expected profitability for the year.
Q3 2026 revenue was $371.1 million, down 2% year-over-year; net income was $19.1 million versus $9.6 million a year earlier
Diluted EPS was $0.29 for the quarter versus $0.15 in the prior-year period; Adjusted EBITDA was $33.9 million, up 24%
Full-year 2026 guidance raised: revenue to $1.44 billion-$1.46 billion (from $1.43 billion-$1.45 billion) and Adjusted EBITDA to $136 million-$138 million (from $129 million-$131 million)
Guardian Pharmacy Services, Inc. said it signed lock-up agreements on September 10, 2026 with its founders, executive officers and certain other employees who hold Class A common stock. The agreements restrict those holders from selling or transferring about 29.9 million shares through September 14, 2027, without the company's consent. The filing is routine disclosure about existing shareholders' trading restrictions, and it ties to a conversion of 13,521,396 Class B shares into Class A on September 27, 2026.
Lock-up agreements effective September 10, 2026 cover about 29.9 million Class A shares held by founders, executives and certain employees.
Restrictions run from the agreement date through September 14, 2027, subject to limited exceptions and company consent.
After the September 27, 2026 conversion of 13,521,396 shares, the company will have 63,320,300 Class A shares outstanding.
Guardian Pharmacy Services reported second-quarter 2026 revenue of $351.8 million, up 2% year over year, and net income of $22.1 million, compared with $8.8 million a year earlier. The company raised its full-year 2026 revenue and Adjusted EBITDA guidance, but net income includes an $8.5 million payor-dispute settlement payment.
Revenue guidance raised to $1.43 billion-$1.45 billion from $1.40 billion-$1.42 billion; Adjusted EBITDA guidance raised to $129 million-$131 million from $122 million-$127 million.
Q2 Adjusted EBITDA was $29.7 million versus $25.0 million a year earlier; diluted EPS was $0.34 versus $0.14.
Net income includes an $8.5 million settlement related to a payor dispute, announced for April 21, 2026.
Company completed the Wellness Concepts acquisition after quarter-end; guidance excludes future acquisitions.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Guardian Pharmacy Services, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →